Article Archive for September 2009
Australian company, Acrux has come out with a positive result from a Phase III trial after evaluating the safety and efficacy of their new testosterone spray, Axiron. The promising results of the late-stage trials of …
The stimulus tax credit of $8,000 for first time home buyers expires on November 30, 2009. That means your new house has to be signed, sealed, and delivered by the last day of November if …
Repros Therapeutics Inc. (NASDAQ:RPRX) has received a verbal warning from the Food and Drug Administration of the United States of America about their drug Proellex. The FDA has informed Repros Therapeutics to resolve all the outstanding …
Hemispherx Biopharma, Inc. (AMEX:HEB) is in the news after it was announced that Dr. Hasegawa the director of the Japanese National Institute of Infectious Diseases presented data on the lead compounds of Ampligen (R) (Poly …
After filing for Chapter 11 for bankruptcy last December it looked like there was no further scope for the Austin-based Introgen Therapeutics. However, a group of Houston investors have come forward and have decided to …
The National Consumer Law Center (NCLC) reviewed 25 programs in 14 states and found no evidence the programs are helping homeowners modify their mortgage loans. The programs are self policed by the financing institutions …
Agri-business may not seem an exciting or glamorous sector for investors to find opportunities, especially when compared to industries that come up with the whiz-bang consumer electronics and communications devices that have …
Allos Therapeutics Inc (Nasdaq:ALTH) must be delighted with joy after getting a green signal by the FDA panel for their injectable drug Folotyn, which will be used for the treatment of peripheral T-cell lymphoma, a rare …
